Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice

Title: Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice
Authors: Koenen, RR; Hundelshausen, P; Nesmelova, IV; Zernecke, A; Liehn, EA; Sarabi, A; Kramp, BK; Piccinini, AM; Paludan, Søren Riis; Kowalska, MA; Kungl, A; Hackeng, TM; Mayo, KH; Weber, C
Source: Koenen, RR, Hundelshausen, P, Nesmelova, IV, Zernecke, A, Liehn, EA, Sarabi, A, Kramp, BK, Piccinini, AM, Paludan, S R, Kowalska, MA, Kungl, A, Hackeng, TM, Mayo, KH & Weber, C 2009, 'Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice', Nature Medicine, vol. 15, pp. 97-103.
Publication Year: 2009
Collection: Aarhus University: Research
Description: Atherosclerosis is characterized by chronic inflammation of the arterial wall due to chemokine-driven mononuclear cell recruitment. Activated platelets can synergize with chemokines to exacerbate atherogenesis; for example, by deposition of the chemokines platelet factor-4 (PF4, also known as CXCL4) and RANTES (CCL5), triggering monocyte arrest on inflamed endothelium. Homo-oligomerization is required for the recruitment functions of CCL5, and chemokine heteromerization has more recently emerged as an additional regulatory mechanism, as evidenced by a mutual modulation of CXCL8 and CXCL4 activities and by enhanced monocyte arrest resulting from CCL5-CXCL4 interactions. The CCL5 antagonist Met-RANTES reduces diet-induced atherosclerosis; however, CCL5 antagonism may not be therapeutically feasible, as suggested by studies using Ccl5-deficient mice which imply that direct CCL5 blockade would severely compromise systemic immune responses, delay macrophage-mediated viral clearance and impair normal T cell functions. Here we determined structural features of CCL5-CXCL4 heteromers and designed stable peptide inhibitors that specifically disrupt proinflammatory CCL5-CXCL4 interactions, thereby attenuating monocyte recruitment and reducing atherosclerosis without the aforementioned side effects. These results establish the in vivo relevance of chemokine heteromers and show the potential of targeting heteromer formation to achieve therapeutic effects
Document Type: article in journal/newspaper
Language: English
ISSN: 1078-8956; 1546-170X
Relation: info:eu-repo/semantics/altIdentifier/pissn/1078-8956; info:eu-repo/semantics/altIdentifier/eissn/1546-170X
Availability: https://pure.au.dk/portal/en/publications/4473bdf0-e624-11dd-8fc3-000ea68e967b
Rights: info:eu-repo/semantics/restrictedAccess
Accession Number: edsbas.63C54715
Database: BASE